Brief: Mineralys Therapeutics Inc Says Topline Data From Trial Are Expected In First Half Of 2024
02/05/2023 13:51
May 2 (Reuters) - Mineralys Therapeutics Inc MLYS.O :
* MINERALYS THERAPEUTICS INC - TOPLINE DATA FROM TRIAL ARE
EXPECTED IN FIRST HALF OF 2024
* MINERALYS THERAPEUTICS INC - SECOND, PIVOTAL TRIAL OF
LORUNDROSTAT IN UNCONTROLLED & RESISTANT HYPERTENSION EXPECTED
TO COMMENCE ENROLLMENT IN H2 2023
* MINERALYS THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
ADVANCE-HTN PIVOTAL TRIAL OF LORUNDROSTAT FOR TREATMENT OF
UNCONTROLLED AND RESISTANT HYPERTENSION
Source text for Eikon: ID:nGNX6Cx7q9
Further company coverage: MLYS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mineralys Therapeutics
See all newsBrief: Mineralys Therapeutics Expands Its Board Of Directors With The Appointments Of Kristine Peterson And Lonnel Coats
Mineralys Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway